2017 Seattle Patient & Survivor Conference
What is Immunotherapy?
Managing Drug Side Effects

From the Pressroom

Dr. Escudier: The Future of RCC Treatment

Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, Fran…

Continue Reading

Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer

The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistical…

Continue Reading

NICE recommends Eisai’s Kisplyx for renal cell carcinoma

Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending len…

Continue Reading